Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Page 1
Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection.
Bilton D, Fajac I, Pressler T, Clancy JP, Sands D, Minic P, Cipolli M, Galeva I, Solé A, Quittner AL, Jumadilova Z, Ciesielska M, Konstan MW; CLEAR-110 Study Group. Bilton D, et al. J Cyst Fibros. 2021 Nov;20(6):1010-1017. doi: 10.1016/j.jcf.2021.05.013. Epub 2021 Jun 16. J Cyst Fibros. 2021. PMID: 34144923 Free PMC article. Clinical Trial.
The CLEAR-110 extension study (ClinicalTrials.gov: NCT01316276; EudraCT: 2011-000443-24) assessed long-term safety, tolerability, and efficacy of ALIS in eligible patients who completed CLEAR-108. ...Mean change from baseline in sputum density of P. aeruginosa at day 672 w …
The CLEAR-110 extension study (ClinicalTrials.gov: NCT01316276; EudraCT: 2011-000443-24) assessed long-term safety, tolerability, and …
Long-term safety study of colistimethate sodium (Colobreathe): Findings from the UK Cystic Fibrosis Registry.
Kaplan S, Lee A, Caine N, Charman SC, Bilton D. Kaplan S, et al. Among authors: bilton d. J Cyst Fibros. 2021 Mar;20(2):324-329. doi: 10.1016/j.jcf.2020.08.001. Epub 2020 Aug 14. J Cyst Fibros. 2021. PMID: 32807645 Free article.
BACKGROUND: As part of the risk management plan in Europe, a long-term observational study was conducted to monitor the safety of colistimethate sodium dry powder for inhalation (CMS-DPI) compared to other inhaled antibiotics. ...The safety profile of CMS-DPI is similar to …
BACKGROUND: As part of the risk management plan in Europe, a long-term observational study was conducted to monitor the safety of col …
Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012-2016 Experience.
Higgins M, Volkova N, Moy K, Marshall BC, Bilton D. Higgins M, et al. Among authors: bilton d. Pulm Ther. 2020 Jun;6(1):141-149. doi: 10.1007/s41030-020-00115-8. Epub 2020 Apr 18. Pulm Ther. 2020. PMID: 32304091 Free PMC article.
INTRODUCTION: In this long-term, postapproval, observational study, data from the US Cystic Fibrosis Foundation Patient Registry and the UK Cystic Fibrosis Registry were used to evaluate the impact of ivacaftor treatment on cystic fibrosis (CF) by comparing outcomes in iva …
INTRODUCTION: In this long-term, postapproval, observational study, data from the US Cystic Fibrosis Foundation Patient Registry and …
Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries.
Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C, Higgins M, Konstan MW, Sawicki GS, Elbert A, Charman SC, Marshall BC, Bilton D. Volkova N, et al. Among authors: bilton d. J Cyst Fibros. 2020 Jan;19(1):68-79. doi: 10.1016/j.jcf.2019.05.015. Epub 2019 Jun 10. J Cyst Fibros. 2020. PMID: 31196670 Free article.
BACKGROUND: Ivacaftor is the first in a class of drugs, CFTR modulators, that target the underlying defect in cystic fibrosis (CF). This long-term observational safety study evaluated CF disease progression in patients treated with ivacaftor in a real-world setting for up …
BACKGROUND: Ivacaftor is the first in a class of drugs, CFTR modulators, that target the underlying defect in cystic fibrosis (CF). This lon …
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE. Haworth CS, et al. Among authors: bilton d. Lancet Respir Med. 2019 Mar;7(3):213-226. doi: 10.1016/S2213-2600(18)30427-2. Epub 2019 Jan 15. Lancet Respir Med. 2019. PMID: 30658914 Clinical Trial.
Although inhaled antibiotics are conditionally recommended for long-term management of non-cystic fibrosis bronchiectasis with frequent exacerbations, there is no approved therapy. ...
Although inhaled antibiotics are conditionally recommended for long-term management of non-cystic fibrosis bronchiectasis with freque …
Investigating the effects of long-term dornase alfa use on lung function using registry data.
Newsome SJ, Daniel RM, Carr SB, Bilton D, Keogh RH. Newsome SJ, et al. Among authors: bilton d. J Cyst Fibros. 2019 Jan;18(1):110-117. doi: 10.1016/j.jcf.2018.08.004. Epub 2018 Aug 29. J Cyst Fibros. 2019. PMID: 30172681 Free article.
However, studies have not evaluated the effectiveness of its long-term use. We aimed to use UK CF Registry data to investigate the effects of one-, two-, three-, four- and five-years of DNase use on lung function to see if the benefits of short-term treatment use ar …
However, studies have not evaluated the effectiveness of its long-term use. We aimed to use UK CF Registry data to investigate the ef …
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor.
Bessonova L, Volkova N, Higgins M, Bengtsson L, Tian S, Simard C, Konstan MW, Sawicki GS, Sewall A, Nyangoma S, Elbert A, Marshall BC, Bilton D. Bessonova L, et al. Among authors: bilton d. Thorax. 2018 Aug;73(8):731-740. doi: 10.1136/thoraxjnl-2017-210394. Epub 2018 May 10. Thorax. 2018. PMID: 29748252 Free PMC article.
As ivacaftor is intended for chronic, lifelong use, understanding long-term effects is important for patients and healthcare providers. ...
As ivacaftor is intended for chronic, lifelong use, understanding long-term effects is important for patients and healthcare provider …
Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data.
Keogh RH, Szczesniak R, Taylor-Robinson D, Bilton D. Keogh RH, et al. Among authors: bilton d. J Cyst Fibros. 2018 Mar;17(2):218-227. doi: 10.1016/j.jcf.2017.11.019. Epub 2018 Jan 6. J Cyst Fibros. 2018. PMID: 29311001 Free PMC article.
Survival did not differ by genotype among individuals diagnosed at birth. Median survival ages at birth in F508del homozygotes were 46years (males) and 41years (females), and similar in non-homozygotes diagnosed at birth. ...Previous studies on estimated surv …
Survival did not differ by genotype among individuals diagnosed at birth. Median survival ages at birth in F508del homozygotes …
24 results